Hanno Riess

Hanno Riess


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 1996
Verified
Journal Article
Closed access
ALA S Lübbe
A S Lübbe
CBC Bergemann
C Bergemann
HRHanno Riess
Hanno Riess
FSF Schriever
F Schriever
PRP Reichardt
P Reichardt
DHD Huhn
D Huhn

9 March 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Uwe PelzerUwe Pelzer
Uwe Pelzer
DADirk Arnold
Dirk Arnold
MGMehmet Goevercin
Mehmet Goevercin
JSJens Stieler
Jens Stieler
BDBernd Doerken
Bernd Doerken
HOHelmut Oettle
Helmut Oettle
Cachexia is a common problem in patients (pts) suffering from upper gastrointestinal cancer. In addition, most of these patients suffer from malabsorption and stenosis of the gastrointestinal tract due to their illness. Various methods of supplementary nutrition (enteral, parenteral) are practised. In patients with advanced pancreatic cancer (APC), phase angle, determined by bio-electrical impedance analysis (BIA), seems to be a survival predictor. The positive influence of BIA determinate predictors by additional nutrition is currently under discussion.

5 December 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HRHanno Riess
Hanno Riess
Uwe PelzerUwe Pelzer
Uwe Pelzer
AHAndreas Hilbig
Andreas Hilbig
JSJens Stieler
Jens Stieler
BOBernhard Opitz
Bernhard Opitz
HOHelmut Oettle
Helmut Oettle
Background: Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer. Enoxaparin, a low molecular weight heparin (LMWH), has proven to be effective for the prevention and treatment of VTE in surgical and general medical patients. Results of some small studies suggest that this benefit might extend to patients with cancer, however, enoxaparin is not currently indicated for this use. This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy. Methods: The aim of this prospective multicenter trial is to compare concomitant treatment with enoxaparin to no anticoagulation in 540 patients. Primary endpoint is the incidence of clinically relevant VTE (symptomatic deep venous thrombosis (DVT) of the leg and/or pelvic and/or pulmonary embolism (PE)) within the first 3 months. Secondary endpoints include the incidence of symptomatic and asymptomatic VTE after 6, 9 and 12 months as well as remission at 3, 6, 9 and 12 months, overall survival and bleeding. Trial registration: isrctn.org identifier CCT-NAPN-16752, controlled-trials.com identifier: ISRCTN02140505. Results: An interim analysis for safety performed after inclusion of 152 patients revealed no increased risk of bleeding (5 pts vs. 6 pts, Chi2: 0.763). Conclusion: PROSPECT is a pivotal study in elucidating the role of low molecular weight heparins in advanced pancreatic cancer. Its results will lead to a new understanding of the role of heparins in the prevention of venous thromboembolism and of their effect on survival, remission rates and toxicity of chemotherapeutic regimens.

7 June 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HRHanno Riess
Hanno Riess
SHS. Haas
S. Haas
UTU. Tebbe
U. Tebbe
HGH.‐E. Gerlach
H.‐E. Gerlach
CAC. Abletshauser
C. Abletshauser
SSS. M. Schellong
S. M. Schellong
Summary. Background: In medically ill patients, no contemporary double‐blind head‐to‐head evaluation of low molecular weight heparin vs. unfractionated heparin (UFH) for the prevention of venous thromboembolic events is available. Objectives: To compare the efficacy and safety of certoparin with those of UFH. Patients/Methods: In this double‐blind, randomized, controlled trial, acutely ill, non‐surgical patients aged ≥ 70 years were randomized to certoparin (3000 U of anti‐factor Xa once daily) or to UFH (5000 IU t.i.d.). The primary endpoint was the composite of proximal deep vein thrombosis as assessed by bilateral compression ultrasonography, symptomatic non‐fatal pulmonary embolism and venous thromboembolism‐related death, and was assessed by a blinded central adjudication committee. Non‐inferiority margins were set at 1.8 for the odds ratio (OR) and 3.45% for the absolute difference. Results: Three thousand two hundred and thirty‐nine patients aged 78.8 ± 6.3 years were treated for 9.1 ± 3.4 days. The incidence of the primary endpoint was 3.94% in the certoparin group and 4.52% in the UFH group, with a difference in proportions of − 0.59% [95% confidence interval (CI) −2.09 to 0.92; P < 0.0001 for non‐inferiority], and an OR of 0.87 (95% CI 0.60–1.26; P = 0.0001 for non‐inferiority). Major bleeding occurred in 0.43% of certoparin‐treated patients and 0.62% of UFH‐treated patients (OR 0.69; 95% CI 0.26–1.83). Any bleeding occurred at 3.20% in certoparin‐treated patients vs. 4.58% in UFH‐treated patients (OR 0.69; 95% CI 0.48–0.99; P < 0.05), and 5.73% of certoparin‐treated patients and 6.63% of UFH‐treated patients experienced serious adverse events. All‐cause mortality was 1.27% in certoparin‐treated patients and 1.36% in UFH‐treated patients. Conclusions: In acutely ill, non‐surgical elderly patients, thromboprophylaxis with certoparin (3000 U of anti‐FXa once daily) was non‐inferior to 5000 IU of UFH t.i.d., with a favorable safety profile.

24 April 2007 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BHBert Hildebrandt
Bert Hildebrandt
MPMaciej Pech
Maciej Pech
ANAnnett Nicolaou
Annett Nicolaou
JLJan M Langrehr
Jan M Langrehr
JKJacek Kurcz
Jacek Kurcz
JRJens Ricke
Jens Ricke
The high complication rates of surgically implanted port catheter systems (SIPCS) represents a major drawback in the treatment of isolated liver neoplasms by hepatic arterial infusion (HAI) of chemotherapy. Interventionally implanted port catheter systems (IIPCS) have evolved into a promising alternative that enable initiation of HAI without laparatomy, but prospective data on this approach are still sparse. Aim of this study was to evaluate the most important technical endpoints associated with the use of IIPCS for the delivery of 5-fluorouracil-based HAI in patients with colorectal liver metastases in a phase 2-study, and to perform a non-randomised comparison with a historical group of patients in which HAI was administered via SIPCS. 41 patients with isolated liver metastases of colorectal cancer were enrolled into a phase II-study and provided with IIPCS between 2001 and 2004 (group A). The primary objective of the trial was defined as evaluation of device-related complications and port duration. Results were compared with those observed in a pre-defined historical collective of 40 patients treated with HAI via SIPCS at our institution between 1996 and 2000 (group B). Baseline characteristics were balanced between both groups, except for higher proportions of previous palliative pre-treatment and elevated serum alkaline phosphatase in patients of group A. Implantation of port catheters was successful in all patients of group A, whereas two primary failures were observed in group B. The frequency of device-related complications was similar between both groups, but the secondary failure rate was significantly higher with the use of surgical approach (17% vs. 50%, p < 0.01). Mean port duration was significantly longer in the interventional group (19 vs. 14 months, p = 0.01), with 77 vs. 50% of devices functioning at 12 months (p < 0.01). No unexpected complications were observed in both groups. HAI via interventionally implanted port catheters can be safely provided to a collective of patients with colorectal liver metastases, including a relevant proportion of preatreated individuals. It appears to offer technical advantages over the surgical approach.

1 December 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
HRHanno Riess
Hanno Riess
PPPaolo Prandoni
Paolo Prandoni
SHSebastian Harder
Sebastian Harder
SKStephan Kreher
Stephan Kreher
RBRupert Bauersachs
Rupert Bauersachs